1. Home
  2. UTMD vs BWAY Comparison

UTMD vs BWAY Comparison

Compare UTMD & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTMD
  • BWAY
  • Stock Information
  • Founded
  • UTMD 1978
  • BWAY 2003
  • Country
  • UTMD United States
  • BWAY Israel
  • Employees
  • UTMD N/A
  • BWAY N/A
  • Industry
  • UTMD Medical/Dental Instruments
  • BWAY Medical/Dental Instruments
  • Sector
  • UTMD Health Care
  • BWAY Health Care
  • Exchange
  • UTMD Nasdaq
  • BWAY Nasdaq
  • Market Cap
  • UTMD N/A
  • BWAY 207.4M
  • IPO Year
  • UTMD N/A
  • BWAY 2019
  • Fundamental
  • Price
  • UTMD $56.04
  • BWAY $9.47
  • Analyst Decision
  • UTMD
  • BWAY Strong Buy
  • Analyst Count
  • UTMD 0
  • BWAY 3
  • Target Price
  • UTMD N/A
  • BWAY $13.17
  • AVG Volume (30 Days)
  • UTMD 17.2K
  • BWAY 54.4K
  • Earning Date
  • UTMD 04-24-2025
  • BWAY 03-11-2025
  • Dividend Yield
  • UTMD 2.17%
  • BWAY N/A
  • EPS Growth
  • UTMD N/A
  • BWAY N/A
  • EPS
  • UTMD 3.96
  • BWAY 0.09
  • Revenue
  • UTMD $40,903,000.00
  • BWAY $41,016,000.00
  • Revenue This Year
  • UTMD N/A
  • BWAY $349.63
  • Revenue Next Year
  • UTMD N/A
  • BWAY $27.16
  • P/E Ratio
  • UTMD $14.18
  • BWAY $59.48
  • Revenue Growth
  • UTMD N/A
  • BWAY 29.04
  • 52 Week Low
  • UTMD $55.81
  • BWAY $4.61
  • 52 Week High
  • UTMD $77.33
  • BWAY $11.79
  • Technical
  • Relative Strength Index (RSI)
  • UTMD 24.89
  • BWAY 42.67
  • Support Level
  • UTMD $56.67
  • BWAY $9.36
  • Resistance Level
  • UTMD $57.61
  • BWAY $9.95
  • Average True Range (ATR)
  • UTMD 0.91
  • BWAY 0.44
  • MACD
  • UTMD -0.05
  • BWAY -0.04
  • Stochastic Oscillator
  • UTMD 7.87
  • BWAY 32.70

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: